Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
      Description

      This study evaluates the value of bortezomib in combination with specified chemotherapies for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

      Conditions
      B-cell Adult Acute Lymphoblastic Leukemia (ALL)Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)Recurrent Adult Acute Lymphoblastic Leukemia (ALL)T-cell Adult Acute Lymphoblastic Leukemia (ALL)
      Talk to us
      RECRUITING
      A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
      Description

      Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks.

      Conditions
      Philadelphia-Negative ALLPhiladelphia-Positive ALLRelapsed ALL, AdultRefractory Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia (ALL)Refractory Acute Lymphoid Leukemia in Relapse
      Talk to us